Pharmacotherapy of hepatic encephalopathy in cirrhosis

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 8, 2010, Pages 1317-1327

  Romero Gómez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Ammonia; Antibiotics; Glutaminase; Hepatic encephalopathy; Inflammation; Rifaximin

Indexed keywords

ASPARTIC ACID; FLUMAZENIL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTITOL; LACTULOSE; METRONIDAZOLE; NEOMYCIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ORNITHINE; PAROMOMYCIN; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; RIFAXIMIN; TUMOR NECROSIS FACTOR;

ABSENCE OF SIDE EFFECTS; AMMONIA FORMATION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTIFICIAL EMBOLISM; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCOCCUS FAECIUM; GASTROINTESTINAL ABSORPTION; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; INFLAMMATION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LENGTH OF STAY; LEUCONOSTOC MESENTEROIDES; LIVER CIRRHOSIS; LIVER DISEASE; NEPHROTOXICITY; NUCLEOTIDE SEQUENCE; NUTRITIONAL SUPPORT; OTOTOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; SACCHAROMYCES; SPONTANEOUS PORTOSYSTEMIC SHUNT; STREPTOCOCCUS THERMOPHILUS; TREATMENT DURATION;

AMMONIA; ANTI-BACTERIAL AGENTS; FLUID THERAPY; FLUMAZENIL; HEPATIC ENCEPHALOPATHY; HUMANS; INTESTINES; LIVER CIRRHOSIS; NUTRITIONAL SUPPORT; PORTASYSTEMIC SHUNT, SURGICAL; PROBIOTICS; RIFAMYCINS;

EID: 77952210764     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003724721     Document Type: Review

References (58)

1. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy- Definition, Nomenclature, Diagnosis, and Quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35(3):716-721
2. Sherlock S. Chronic portal-systemic encephalopathy: update 1987. Gut 1987;28:1043-1048
3. Nance FC, Kline DG. Eck's fistula encephalopathy in germ-free dogs. Ann Surg 1971;174:856-861
4. Warren KS, Newton WL. Portal and peripheral blood ammonia concentrations in germ-free and conventional guinea pigs. Am J Pysiol 1959;197:717-720
5. Weber FJL, Veach GL. The importance of the small intestine in gut ammonium production in the fasting dog. Gastroenterology 1979;77:235-240
6. Olde Damink SW, Jalan R, Redhead DN, et al. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002;36:1163-1171
7. Romero-Gomez M, Grande L, Camacho I. Prognostic value of altered oral glutamine challenge in patients with minimal hepatic encephalopathy. Hepatology 2004;39:939-943
8. James LA, Lunn PG, Middleton S, et al. Distribution of glutaminase and glutamine synthase activities in the human gastrointestinal tract. Clin Sci 1998;94:313-319
9. Romero-Gomez M, Ramos-Guerrero R, Grande L, et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J Hepatol 2004;41:49-54
10. Romero-Gomez M. Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2005;20:319-325
11. Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 1995;15:133-159
12. Hawkins RA, Jessy J, Mans AM, et al. Neomycin reduces the intestinal production of ammonia from glutamine. Adv Exp Med Biol 1994;368:125-134
13. Taylor L, Liu X, Newsome W, et al. Isolation and characterization of the promoter region of the rat kidney-type glutaminase gene. Biochim Biophys Acta 2001;1518:132-136
14. Elgadi KM, Meguid RA, Qian M, et al. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics 1999;1:51-62
15. Del Campo JA, Jover M, Royo JL, et al. A microsatellite in the promoter region of the GLS gene predicts the risk of hepatic encephalopathy: functional analysis using luciferase reporter. Hepatology 2009;50:320A
16. Jalan R, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond) 2004;106:467-474
17. Shawcross DL, Davies NA, Williams R, et al. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 2004;40:247-254
18. Malaguarnera M, Greco F, Barone G, et al. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52:3259-3265
19. Cauli O, Rodrigo R, Piedrafita B, et al. Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts. Hepatology 2007;46:514-519
20. Wright G, Jalan R. Ammonia and inflammation in the pathogenesis of hepatic encephalopathy: pandora's box? Hepatology 2007;46:291-294 (Pubitemid 47344761)
21. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(Suppl 1):13-27
22. Testa R, Eftimiadi C, Sukkar GS, et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985;11:387-392
23. De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986;12:979-981
24. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993;13:109-118
25. Mas A, Rodés J, Sunyer L, et al. Comparison of rifaximin and actitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003;38:527-528
26. Festi D, Vestito A, Mazzella G, et al. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion 2006;73(Suppl 1):94-101
27. Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacology 2008;28:1019-1032
28. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin Treatment in Hepatic Encephalopathy. N Eng J Med 2010;362:1071-1081
29. Leevy B, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Schi 2007;52:737-741
30. Maclayton DO, Eaton-Maxwell Al. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother 2009;43:77-84
31. Sharma P, Sharma BC, Puri V, et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008;20:506-511
32. Loguercio C, Abbiati R, Rinaldi M, et al. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995;23:39-46
33. Malaguarnera M, Gargante MP, Malaguarnera G, et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010;22(2):199-206
34. Bajaj JS, Saeian K, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008;103(7):1707-1715
35. Liu Q, Duan ZP, Ha DK, et al. Symbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-1449
36. Masini A, Efrati C, Merli M, et al. Effect of lactitol on blood ammonia response to oral glutamine challenge in cirrhotic patients: evidence for an effect of non-absorbable disaccharides on small intestine ammonia generation. Am J Gastroenterol 1999;94:3323-3327
37. Jiang Q, Jiang XH, Zheng MH, et al. Rifaximin versus non-absorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008;20:1064-1070
38. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004;328:1046
39. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive function and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007;45:549-559
40. Sharma BC, Sharma P, Agrawal A, et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885-891
41. Sharma P, Sharma BC, Sarin SK. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis. Liver Int 2009;29:1365-1371
42. Dasarathy S, Yang Y, Muc S, et al. Ammonia causes elevated skeletal muscle myostatin and reduced myoblast proliferation and differentiation. Hepatology 2009;50:22A
43. Córdoba J, López-Hellín J, Planas M, et al. Normal protein diet for episodic hepatic encephalopathy. J Hepatol 2004;41:38-43
44. Les I, Planas M, Cardenas G, et al. Effects of the proteins of the diet in patients with cirrhosis and prior episode of hepatic encephalopathy. A long-term randomized study. Hepatology 2009;50:24A
45. Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998;28:856-864
46. Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornitine-Laspartate infusions in patients with cirrhosis and hepatic encephalopathy: result of a placebo-controlled, double blind study. Hepatology 1997;25:1351-1360
47. Jiang Q, Jiang XH, Zheng MH, et al. L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 2009;24:9-14
48. Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology 2006;44:788-794
49. Als-Nielsen B, Gluud LL, Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst Rev 2004;(2):CD002798
50. Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998;28:374-378
51. Riggio O, Efrati C, Catalano C, et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2005;42:1158-1165
52. Boixadera H, Tomasello A, Quiroga S, et al. Successful embolization of a spontaneous mesocaval shunt using the Amplatzer vascular plug II. Cardiovasc Intervent Radiol 2010. (In press)
53. Maleux G, Heye S, Verslype C, et al. Management of transjugular intrahepatic porto-systemic shunt induced refractory hepatic encephalopathy with the parallel technique: results of a clinical follow-up study. J Vasc Interv Radiol 2007;18:986-992
54. Bureau C, Garcia-Pagan JC, Otal P, et al. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 2004;126:469-475
55. Randolph C, Hilsabeck R, Kato A, et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver Int 2009;29:629-635
56. Kircheis G, Wettstein M, Timmermann L, et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002;35:357-366
57. Romero-Gómez M. Critical flicker frequency: it is time to break down barriers surrounding minimal hepatic encephalopathy. J Hepatol 2007;47:10-11 (Pubitemid 46817698)
58. Romero-Gómez M, Córdoba J, Jover R, et al. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007;45:879-885